{"analyses":[{"ciLowerLimit":"11.23","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"31.51","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0003","paramType":"Common Risk Difference on Response Rate","paramValue":"21.37","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"1.827","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"8.956","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0003","paramType":"Odds Ratio (OR)","paramValue":"4.045","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"25.93","upperLimit":"41.40","value":"33.33"},{"groupId":"OG001","lowerLimit":"5.56","upperLimit":"21.29","value":"11.84"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"76"}],"units":"Participants"}],"description":"RBC-TI Response was defined as the absence of any Red Blood Cells (RBC) transfusion during any consecutive 84-day (12-week) period (ie, Days 1 to 84, Days 2 to 85, Days 3 to 86, etc.) during the first 48 weeks of treatment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Luspatercept 1.0 mg/Kg SC on Day 1 of each 21-day treatment cycle","id":"OG000","title":"Luspatercept"},{"description":"Placebo (Volume equivalent to experimental arm) SC on Day 1 of each 21-day treatment cycle","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"From Week 1 through Week 48 of study treatment","title":"Percentage of Participants Who Achieved Red Blood Cell Transfusion Independence (RBC-TI) ≥ 12 Weeks From Week 1 to Week 48","type":"SECONDARY","unitOfMeasure":"Percent of Participants"}